Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Compare
Compare
Traded in other countries / regions
FARN.UKFARON.Finland4FR.GermanyFPHAF.USA IPO Date
2019-12-03Description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.36 | |||||
| Equity-to-Asset | 0.04 | |||||
| Debt-to-Equity | 9.22 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4.9 | |||||
| 3-Year EPS without NRI Growth Rate | -7.4 | |||||
| 3-Year FCF Growth Rate | 3.2 | |||||
| 3-Year Book Growth Rate | -74 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.35 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.9 | |||||
| 9-Day RSI | 46.9 | |||||
| 14-Day RSI | 48.31 | |||||
| 3-1 Month Momentum % | -29.24 | |||||
| 6-1 Month Momentum % | 63.59 | |||||
| 12-1 Month Momentum % | -43.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.45 | |||||
| Quick Ratio | 1.45 | |||||
| Cash Ratio | 1.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | 0.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -286.54 | |||||
| ROIC % | -398.75 | |||||
| 3-Year ROIIC % | -636.9 | |||||
| ROC (Joel Greenblatt) % | -10779.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 159.81 | |||||
| EV-to-EBIT | -6.62 | |||||
| EV-to-Forward-EBIT | -3.73 | |||||
| EV-to-EBITDA | -6.69 | |||||
| EV-to-Forward-EBITDA | -6.88 | |||||
| EV-to-Forward-Revenue | 768.72 | |||||
| EV-to-FCF | -8.44 | |||||
| Earnings Yield (Greenblatt) % | -15.11 | |||||
| FCF Yield % | -11.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Faron Pharmaceuticals Oy Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.379 | ||
| Beta | 3 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 113.8 | ||
| 14-Day RSI | 48.31 | ||
| 14-Day ATR (€) | 0.157507 | ||
| 20-Day SMA (€) | 2.01345 | ||
| 12-1 Month Momentum % | -43.51 | ||
| 52-Week Range (€) | 1.054 - 3.429525 | ||
| Shares Outstanding (Mil) | 104.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Faron Pharmaceuticals Oy Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Faron Pharmaceuticals Oy Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Faron Pharmaceuticals Oy Frequently Asked Questions
What is Faron Pharmaceuticals Oy(OHEL:FARON)'s stock price today?
The current price of OHEL:FARON is €2.05. The 52 week high of OHEL:FARON is €3.43 and 52 week low is €1.05.
When is next earnings date of Faron Pharmaceuticals Oy(OHEL:FARON)?
The next earnings date of Faron Pharmaceuticals Oy(OHEL:FARON) is 2025-03-13 Est..
Does Faron Pharmaceuticals Oy(OHEL:FARON) pay dividends? If so, how much?
Faron Pharmaceuticals Oy(OHEL:FARON) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers